mardi 11 octobre 2016

Onco Actu du 11 octobre 2016

2. Etiologie

'No link' between night shifts and breast cancer risk [NHS Choices]

4. Dépistage, diagnostic et pronostic

A Noninvasive Approach May Identify Glioblastoma Patients Suitable for Antiangiogenic Therapy [AACR]

Computers still aren't close to replacing doctors for diagnosing disease [Vox]

5. Traitements

A new strategy for choosing cancer drugs [MIT News]

5.12 Immunothérapies

Immuno-oncology: AACR Partners with FDA to Accelerate the Pace of Progress [Cancer Researh Catalyst]

5.2 Pharma

Clovis' Drug Data Deja Vu [Bloomberg]

Bristol's Failure of Leadership [Bloomberg]

Ziopharm Breast Cancer Gene Therapy Tied to 'Higher Than Expected' Toxicity [The Street]

5.2.1 Pharma - Partenariats

In the midst of an R&D shift, Takeda inks $790M cancer collab with Crescendo [FierceBiotech]

5.2.3 Pharma - économie

Even High-Flying Tesaro and Its Ovarian Cancer Drug Has a Bear Thesis. Here It Is, Explained [The Street]

5.3 Traitements - FDA, EMA,...

The Sarepta dilemma: Bioethics expert Arthur Caplan says it’s time to rethink how to regulate compassion [EndPoints]

How the FDA Manipulates the Media [Scientific American]

5.4 Traitements - Economie

This federal drug discount program is actually boosting cancer care costs [STAT]

What outrage? Ariad raises price of its leukemia drug four times so far this year [STAT]

5.6 ESMO

Checkpoints In Lung Cancer, and Other Oncology News From Europe [Xconomy]

5.6.11 ESMO- Rein

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC) [Pfizer]

5.6.14 ESMO - Ovaire

Superlative data from NOVA: A Star is Born [OBR]

5.6.15 ESMO - VADS

Meta-Analysis Confirms Superiority of Concomitant Over Induction Chemotherapy in Non-Metastatic HNSCC [ESMO]

5.6.2 ESMO - Divers

The NETwork! Translational Programme Facilitates Genomic Analysis of Neuroendocrine Tumours [ESMO]

Metformin Significantly Lowers the Risk of Cancer Progression in Patients with Diabetes and Advanced pNETs [ESMO]

5.6.4 ESMO - Poumon

A Very Long Ovation for Keytruda and a Polite One for Opdivo at ESMO 2016 Is Not “the End of the Story” in NSCLC [OBR]

OAK Bears Fruit: Roche’s Tecentriq Enters the Heavily Played Lung Cancer Field [OBR]

ARIAD Presents Updated Long-Term Follow-up Results from the Phase 1/2 Trial on Investigational Drug Brigatinib at 2016 ESMO Meeting [Ariad]

Keytruda vs. Opdivo: No Contest [In the Pipeline]

Clinical Benefit Demonstrated with Everolimus and Pasireotide LAR Alone or in Combination in the First Randomised, Prospective Study Entirely Dedicated to Advanced Lung and Thymic Carcinoids [ESMO]

Bristol lung-cancer setback puts rival Merck drug in driver seat [Reuters]

Doctors grapple with best use of potent new cancer drugs [Reuters]

5.6.5 ESMO - Mélanome & Peau

Baseline Genetic Features Elucidated in Responding and Non-Responding Patients with BRAFV600-Mutated Melanoma [ESMO]

PD-L1 Expression as a Biomarker for Checkpoint Inhibitors Response in Patients with Advanced Melanoma [ESMO]

5.6.6 ESMO - Sein

MONALEESA-2: Smiles Abound as First Line Ribociclib plus Letrozole Significantly Improves Progression-Free Survival [OBR]

6.1 Observation

Rise in Oropharyngeal Cancer Incidence Not Solely Driven by HPV [AACR]

Take a Number: Cancer in Retreat on One Front: Fewer Children Are Dying [NY Times]

6.4 Médico-éco

Breast cancer chemo costs vary despite similar effectiveness [Reuters]

6.6 Publications

Cancer biologist says Nature journal “censored” his News & Views, retracts it [Retraction Watch]

6.9 Controverses

Evidence-based medicine guidelines versus patient wishes [Respectful Insolence]